Profile of alisporivir and its potential in the treatment of hepatitis C. - Wikidata - awgldk - TriplyDB

Profile of alisporivir and its potential in the treatment of hepatitis C.

Profile of alisporivir and its potential in the treatment of hepatitis C.

http://www.wikidata.org/entity/Q34329744

about

The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection Virus-host interactomics: new insights and opportunities for antiviral drug discovery Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).Both Cyclophilin Inhibitors and Direct-Acting Antivirals Prevent PKR Activation in HCV-Infected Cells.The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.Novel indole-2-carboxamide compounds are potent broad-spectrum antivirals active against western equine encephalitis virus in vivo.Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Intrinsic disorder mediates hepatitis C virus core-host cell protein interactions.Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories A Proline-Tryptophan Turn in the Intrinsically Disordered Domain 2 of NS5A Protein Is Essential for Hepatitis C Virus RNA Replication Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents.A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ.Host-targeting agents in the treatment of hepatitis C: a beginning and an end?Influenza virus-host interactomes as a basis for antiviral drug development.Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress.Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.The role of immunophilins in viral infection.New treatments for chronic hepatitis C: an overview for paediatricians.ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.Asunaprevir for hepatitis C: a safety evaluation.Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach.Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.Targeting Endoplasmic Reticulum and/or Mitochondrial Ca2+ Fluxes as Therapeutic Strategy for HCV Infection.Host-targeting therapies for hepatitis C virus infection: current developments and future applications.Mathematical Analysis of Viral Replication Dynamics and Antiviral Treatment Strategies: From Basic Models to Age-Based Multi-Scale Modeling Current and future targets of antiviral therapy in the hepatitis C virus life cycle Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies A Systems Approach to Study Immuno- and Neuro-Modulatory Properties of Antiviral Agents

P2860

Q26800446-BD716931-854D-4807-A43A-EC95F1683D04 Q27468931-14D2C5FE-E03F-4457-9A04-C60228BA862D Q28652236-58C87AB7-B219-495D-81F8-45111A0DE239 Q31051529-9F568D89-69C6-49F8-8D68-1705F06C2C14 Q33424900-9831673A-0E60-4C98-AEE2-A4F726936C4C Q33565080-5211B0D1-8E84-4359-B91B-D6B21E49CA2A Q33797891-54EBAEFB-078B-460F-841C-C9B39B5C06B4 Q34261735-7D05A357-98F4-439E-8C09-49EA67915CF3 Q34580799-98B05D86-4D03-4E26-82ED-72CA626CBB3E Q35044139-33E2E761-9301-4F25-9BEE-6AB1E2E9D37D Q35385005-AAB44152-6680-4D74-9A7B-58C5480D414E Q35905354-5A869CD2-E1FE-45C5-9F8E-F1E4B08133C3 Q36744474-418A12FE-3630-4F1E-B071-5335675222DC Q36904981-BAE0240B-B439-4511-9D38-55C6391B2EC0 Q37263877-21FA8265-D57A-4022-A246-F62390DA54A3 Q37676364-EAE1AD92-CB4F-41DC-91C2-E4AD2A6A4135 Q37737812-D49FDFE7-AD8C-4AEA-B644-50745A376B0D Q38174062-41E21825-6078-4B95-8A0A-A13E537549B3 Q38193198-BD3D8639-D2DB-4C4B-9F3B-C705349427BD Q38244931-F2DAF7DC-4F89-41D9-8EB0-71F2AE4CA5DF Q38274889-312B84CE-DF01-431E-954A-D8842E0F60EE Q38282842-6C0BC488-B85A-44FC-885A-375ACD05379E Q38387667-7F51714F-AC78-4CFC-A196-D6A5F1EA0196 Q38578458-CEE90B01-4E23-4F35-A157-43566A9EDC8A Q38871364-398C2E45-B9D0-432B-81DE-83743E5504AB Q38990715-16F8ACDE-CE57-4935-A1DC-8A9EB92E559A Q39018864-43DECB3C-2577-4E9E-8BB9-66D2367D97B9 Q39810813-F9F170BB-08E0-40AB-AF8F-6900B4B0EB79 Q41654386-E33E3C51-BBAE-4BA9-B0E2-CF48A1338E53 Q42181792-43B3FF78-8ABC-4811-A240-4B8F3AF78A99 Q42196934-64718042-A898-4725-90F5-B95EE08728CE Q42246268-015D8DD4-0276-4F21-A107-2800056867C5 Q55137403-5F392F5B-855C-42E8-980E-030FBD47AEE4 Q55280981-F02B40DD-84FB-4B9E-A8E6-3C41C4124FC1 Q56000943-5B6AD43E-887A-4EA4-A23E-CC9923DB18F5 Q57071775-75F4661B-D10D-4B75-B533-42FB957499CC Q57946696-DBE9900E-E8F2-4F7E-BB7F-9BA9BAD91706 Q58787671-F7ADFA1B-0504-4E1F-9985-A62990C2CE82

P2860

Profile of alisporivir and its potential in the treatment of hepatitis C.

http://www.wikidata.org/entity/Q34329744

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Profile of alisporivir and its potential in the treatment of hepatitis C.

@ast

Profile of alisporivir and its potential in the treatment of hepatitis C.

@en

Profile of alisporivir and its potential in the treatment of hepatitis C.

@nl

type

label

Profile of alisporivir and its potential in the treatment of hepatitis C.

@ast

Profile of alisporivir and its potential in the treatment of hepatitis C.

@en

Profile of alisporivir and its potential in the treatment of hepatitis C.

@nl

prefLabel

Profile of alisporivir and its potential in the treatment of hepatitis C.

@ast

Profile of alisporivir and its potential in the treatment of hepatitis C.

@en

Profile of alisporivir and its potential in the treatment of hepatitis C.

@nl

P1433

Q34329744-C5BD56F5-BEF8-451B-94F5-167A2F529609

P1476

Q34329744-8C4695B0-6B69-4F21-8AFD-0C31EEBE25A6

P2093

Q34329744-267D56C6-7D39-47C0-97D2-6EEEFF3CDE0C

Q34329744-34865E2D-1B4F-49B7-85FD-E8D1DC4849AA

P2860

Q34329744-09BBDD77-5EA0-4A29-898E-3E2E44023F58

Q34329744-1411F558-F11C-4628-BB25-DFC96405EAF1

Q34329744-165C50BE-7C94-4F84-B8EB-9A4901E36EBD

Q34329744-1A899187-AD46-4BEE-BAA2-1E6D789E25B7

Q34329744-1EECA250-AF55-49B7-AC16-AEB2966DFA80

Q34329744-1F429593-BFC9-4E72-9946-93CC2690A229

Q34329744-24B2897B-1D06-486E-A7EF-59BAA135DA11

Q34329744-2545FB13-EAB0-47CA-8646-A5C17F8116A9

Q34329744-2C89F731-15E9-44A9-AD52-4397E429C962

Q34329744-37758434-E150-405A-90CC-D9F1B5819458

P304

Q34329744-EFD68659-27EE-4D34-8792-0BE953149A30

P31

Q34329744-1034BF9C-30D0-42ED-BD4E-560A55EECF24

Q34329744-70504EED-EB08-4541-94D7-61CE0BC822B6

P356

Q34329744-06FCCF07-6E59-441A-AE1F-62A78B35989E

P407

Q34329744-E56EE700-B7E1-4ED5-B341-095F788BC0A2

P478

Q34329744-5BAB206A-9B50-4FE4-8ED7-FF9A1EC8D3F1

P577

Q34329744-2D738DE6-F6DF-4F44-B03C-53D999D7DF87

P698

Q34329744-D7D1012D-8CD3-4035-B035-66F6BDB71FCF

P921

Q34329744-3C0D0561-4343-4542-8F96-EE6B12683E63

Q34329744-DF71AC02-52B2-42D7-9396-599310C17DE8

Q34329744-E7E5290A-35AA-4742-8880-A8F8D63C9DC8

P932

Q34329744-A8E13AB9-9E2D-4685-9CB5-51115166EF14

P356

P1433

Drug Design, Development and Therapy

P1476

Profile of alisporivir and its potential in the treatment of hepatitis C.

@en

P2093

Kai Lin

http://www.w3.org/2001/XMLSchema#string

Philippe A Gallay

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of hepatitis C virus infection

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolyl cis/trans Isomerase Activity of Cyclophilins A and B

Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex

Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

Identification of Hepatitis C Virus NS5A Inhibitors

SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro

P304

105-115

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S30946

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23440335

http://www.w3.org/2001/XMLSchema#string

P921

polycyclic compound

P932

3578503

http://www.w3.org/2001/XMLSchema#string